Back to search results

Digital Lifestyle Coaching for Alzheimer's Prevention in APOE4 Carriers

This study, called Wellderly Brain, is looking at whether virtual lifestyle coaching can help prevent Alzheimer's disease in people aged 60-80 who carry the APOE4 gene, which increases their risk. You would need to be a 23andMe participant with the APOE4 genetic variant and have a smartphone. The study will compare 16 virtual coaching sessions over 52 weeks, focusing on activity, sleep (with an Oura ring), and an anti-inflammatory diet, against an education-only group. Researchers will measure a blood marker called plasma pTau217 concentration at months 1, 6, and 12 to see if the coaching has a positive effect. The study aims to enroll 1200 participants and is currently recruiting.

Study design
This is a randomized study, meaning participants are assigned by chance to one of two groups. It plans to enroll 1200 participants.
What's involved
If you are in the coaching group, you would have 16 virtual coaching sessions over 52 weeks. You would also need to perform a self-administered saliva test at screening.
Compensation
Not stated in the trial record.
Follow-up
Your plasma pTau217 concentration will be measured at Month 1, Month 6, and Month 12.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07646054

Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers

Not Yet Recruiting
NAAges 60–80InterventionalPrevention
Scripps Translational Science Institute
~1,200 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:Education

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Plasma pTau217 Concentration
Measured over Month 1, Month 6, Month 12

Conditions

Mild Cognitive Impairment (MCI)
Alzheimer Disease (AD)

Explore related trials

Alzheimer's DiseaseAPOE*4 Allele

NCT07646054

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Scripps Translational Research Institute

    La Jolla, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Eric J Topol, MD · PRINCIPAL_INVESTIGATOR · Scripps Translational Research Institute

Who to contact

Katie Quartuccio
[email protected]
858-784-5219
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Current 23andMe Research participant with APOE4 positivity genetic variant
Age 60 to 80 at time of consent
Have access to an Android or Apple iPhone smartphone device and able to download study apps
Lives in the United States and able to send and receive US Mail
Able and willing to perform a self-administered saliva test at screening\*for organic outreach only.
Able and willing to perform a self-administered finger prick blood collection at three time points throughout the study.

Exclusion

Non-English speaking
Lives outside of the United States
Currently taking or planning on taking GLP-1 medications (Exenatide, Liraglutide, Albiglutide, Dulaglutide, Semaglutide or Tirzepatide) within the next 12 months
Established diagnosis of Mild Cognitive Impairment, Alzheimer's Disease or other Neurodegenerative Disease (Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease, Multiple Sclerosis or Frontotemporal Dementia).
Current or past Oura Ring user (any Oura Ring use in the last 12 months)

What this trial measures

  • Plasma pTau217 ConcentrationMonth 1, Month 6, Month 12

    Plasma phosphorylated tau 217 (pTau217) concentration will be measured from self-collected dried blood spot samples at three timepoints across the 12-month active monitoring period. Both absolute concentration at each time point and change from baseline will be assessed.